240 related articles for article (PubMed ID: 14648717)
1. CHEK2 1100delC is not a risk factor for male breast cancer population.
Syrjäkoski K; Kuukasjärvi T; Auvinen A; Kallioniemi OP
Int J Cancer; 2004 Jan; 108(3):475-6. PubMed ID: 14648717
[TBL] [Abstract][Full Text] [Related]
2. BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases.
Falchetti M; Lupi R; Rizzolo P; Ceccarelli K; Zanna I; Calò V; Tommasi S; Masala G; Paradiso A; Gulino A; Giannini G; Russo A; Palli D; Ottini L
Breast Cancer Res Treat; 2008 Jul; 110(1):161-7. PubMed ID: 17661168
[TBL] [Abstract][Full Text] [Related]
3. CHEK2*1100delC and male breast cancer risk in Israel.
Ohayon T; Gal I; Baruch RG; Szabo C; Friedman E
Int J Cancer; 2004 Jan; 108(3):479-80. PubMed ID: 14648719
[No Abstract] [Full Text] [Related]
4. CHEK2 1100delC and male breast cancer in the Netherlands.
Wasielewski M; den Bakker MA; van den Ouweland A; Meijer-van Gelder ME; Portengen H; Klijn JG; Meijers-Heijboer H; Foekens JA; Schutte M
Breast Cancer Res Treat; 2009 Jul; 116(2):397-400. PubMed ID: 18759107
[TBL] [Abstract][Full Text] [Related]
5. Role of CHEK2*1100delC in unselected series of non-BRCA1/2 male breast cancers.
Neuhausen S; Dunning A; Steele L; Yakumo K; Hoffman M; Szabo C; Tee L; Baines C; Pharoah P; Goldgar D; Easton D
Int J Cancer; 2004 Jan; 108(3):477-8. PubMed ID: 14648718
[No Abstract] [Full Text] [Related]
6. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.
Meijers-Heijboer H; van den Ouweland A; Klijn J; Wasielewski M; de Snoo A; Oldenburg R; Hollestelle A; Houben M; Crepin E; van Veghel-Plandsoen M; Elstrodt F; van Duijn C; Bartels C; Meijers C; Schutte M; McGuffog L; Thompson D; Easton D; Sodha N; Seal S; Barfoot R; Mangion J; Chang-Claude J; Eccles D; Eeles R; Evans DG; Houlston R; Murday V; Narod S; Peretz T; Peto J; Phelan C; Zhang HX; Szabo C; Devilee P; Goldgar D; Futreal PA; Nathanson KL; Weber B; Rahman N; Stratton MR;
Nat Genet; 2002 May; 31(1):55-9. PubMed ID: 11967536
[TBL] [Abstract][Full Text] [Related]
7. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
[TBL] [Abstract][Full Text] [Related]
8. CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population.
Hallamies S; Pelttari LM; Poikonen-Saksela P; Jekunen A; Jukkola-Vuorinen A; Auvinen P; Blomqvist C; Aittomäki K; Mattson J; Nevanlinna H
BMC Cancer; 2017 Sep; 17(1):620. PubMed ID: 28874143
[TBL] [Abstract][Full Text] [Related]
9. The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.
Oldenburg RA; Kroeze-Jansema K; Kraan J; Morreau H; Klijn JG; Hoogerbrugge N; Ligtenberg MJ; van Asperen CJ; Vasen HF; Meijers C; Meijers-Heijboer H; de Bock TH; Cornelisse CJ; Devilee P
Cancer Res; 2003 Dec; 63(23):8153-7. PubMed ID: 14678969
[TBL] [Abstract][Full Text] [Related]
10. Excess breast cancer risk in first degree relatives of CHEK2∗1100delC positive familial breast cancer cases.
Adank MA; Verhoef S; Oldenburg RA; Schmidt MK; Hooning MJ; Martens JW; Broeks A; Rookus M; Waisfisz Q; Witte BI; Jonker MA; Meijers-Heijboer H
Eur J Cancer; 2013 May; 49(8):1993-9. PubMed ID: 23415889
[TBL] [Abstract][Full Text] [Related]
11. Absence of CHEK2*1100delC mutation in families with hereditary breast cancer in North America.
Iniesta MD; Gorin MA; Chien LC; Thomas SM; Milliron KJ; Douglas JA; Merajver SD
Cancer Genet Cytogenet; 2010 Oct; 202(2):136-40. PubMed ID: 20875877
[TBL] [Abstract][Full Text] [Related]
12. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.
Weischer M; Bojesen SE; Ellervik C; Tybjaerg-Hansen A; Nordestgaard BG
J Clin Oncol; 2008 Feb; 26(4):542-8. PubMed ID: 18172190
[TBL] [Abstract][Full Text] [Related]
13. Frequency of CHEK2 mutations in a population based, case-control study of breast cancer in young women.
Friedrichsen DM; Malone KE; Doody DR; Daling JR; Ostrander EA
Breast Cancer Res; 2004; 6(6):R629-35. PubMed ID: 15535844
[TBL] [Abstract][Full Text] [Related]
14. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.
Vahteristo P; Bartkova J; Eerola H; Syrjäkoski K; Ojala S; Kilpivaara O; Tamminen A; Kononen J; Aittomäki K; Heikkilä P; Holli K; Blomqvist C; Bartek J; Kallioniemi OP; Nevanlinna H
Am J Hum Genet; 2002 Aug; 71(2):432-8. PubMed ID: 12094328
[TBL] [Abstract][Full Text] [Related]
15. Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results.
Pritzlaff M; Summerour P; McFarland R; Li S; Reineke P; Dolinsky JS; Goldgar DE; Shimelis H; Couch FJ; Chao EC; LaDuca H
Breast Cancer Res Treat; 2017 Feb; 161(3):575-586. PubMed ID: 28008555
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer.
Guénard F; Pedneault CS; Ouellette G; Labrie Y; Simard J; ; Durocher F
Genet Test Mol Biomarkers; 2010 Aug; 14(4):515-26. PubMed ID: 20722467
[TBL] [Abstract][Full Text] [Related]
17. The CHEK2 1100delC mutation is not present in Korean patients with breast cancer cases tested for BRCA1 and BRCA2 mutation.
Choi DH; Cho DY; Lee MH; Park HS; Ahn SH; Son BH; Haffty BG
Breast Cancer Res Treat; 2008 Dec; 112(3):569-73. PubMed ID: 18175216
[TBL] [Abstract][Full Text] [Related]
18. CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women.
Adank MA; Jonker MA; Kluijt I; van Mil SE; Oldenburg RA; Mooi WJ; Hogervorst FB; van den Ouweland AM; Gille JJ; Schmidt MK; van der Vaart AW; Meijers-Heijboer H; Waisfisz Q
J Med Genet; 2011 Dec; 48(12):860-3. PubMed ID: 22058428
[TBL] [Abstract][Full Text] [Related]
19. German populations with infrequent CHEK2*1100delC and minor associations with early-onset and familial breast cancer.
Rashid MU; Jakubowska A; Justenhoven C; Harth V; Pesch B; Baisch C; Pierl CB; Brüning T; Ko Y; Benner A; Wichmann HE; Brauch H; Hamann U;
Eur J Cancer; 2005 Dec; 41(18):2896-903. PubMed ID: 16239104
[TBL] [Abstract][Full Text] [Related]
20. Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer.
Laitman Y; Kaufman B; Lahad EL; Papa MZ; Friedman E
Isr Med Assoc J; 2007 Nov; 9(11):791-6. PubMed ID: 18085035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
